Merck Launches Gardasil In India At Half U.S. Price
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Merck's India affiliate MSD Pharmaceuticals has launched blockbuster cervical cancer vaccine Gardasil in India at $170 (Rs 8,400) per three-dose regimen, nearly half of its U.S. price of $350
You may also be interested in...
U.S. National Institutes Of Health, India's Cadila Healthcare Join Forces To Develop A New HPV Vaccine
SINGAPORE - India's Zydus Cadila has joined hands with the U.S.-based National Institutes of Health to develop a new prophylactic vaccine against human papilloma virus - known to be a major cause of cervical cancer
U.S. National Institutes Of Health, India's Cadila Healthcare Join Forces To Develop A New HPV Vaccine
SINGAPORE - India's Zydus Cadila has joined hands with the U.S.-based National Institutes of Health to develop a new prophylactic vaccine against human papilloma virus - known to be a major cause of cervical cancer
Merck, Indian Government In Talks For Gardasil Supplies; Aim To Enroll 600 For Mandatory Trials
MUMBAI - Merck has initiated talks with the Indian health ministry to supply Gardasil vaccines for use in government health institutions. Merck has launched the human papillomavirus vaccine Gardasil in India at half its international price and intends to make the drug available to a larger population base through the government's national immunization programs (PharmAsia News, Oct. 14, 2008)